A share price of MoonLake Immunotherapeutics [MLTX] is currently trading at $8.66, up 2.73%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MLTX shares have gain 38.67% over the last week, with a monthly amount drifted -85.43%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
MoonLake Immunotherapeutics [NASDAQ: MLTX] stock has seen the most recent analyst activity on October 02, 2025, when H.C. Wainwright downgraded its rating to a Neutral. Previously, Goldman downgraded its rating to Neutral on October 01, 2025, and kept the price target unchanged to $7. On September 30, 2025, downgrade downgraded it’s rating to Underperform but maintained its price target of $2 on the stock. Citigroup downgraded its rating to a Neutral but stick to its price target of $5 on September 30, 2025. Stifel downgraded its rating to a Hold but $13 remained the price target by the analyst firm on September 29, 2025. RBC Capital Mkts downgraded its rating to Sector Perform for this stock on September 29, 2025, but kept the price target unchanged to $10. In a note dated September 29, 2025, Jefferies downgraded an Hold rating on this stock but restated the target price of $8.
MoonLake Immunotherapeutics experienced fluctuations in its stock price throughout the past year between $5.95 and $62.75. Currently, Wall Street analysts expect the stock to reach $13 within the next 12 months. MoonLake Immunotherapeutics [NASDAQ: MLTX] shares were valued at $8.66 at the most recent close of the market. An investor can expect a potential return of 50.12% based on the average MLTX price forecast.
Analyzing the MLTX fundamentals
Gross Profit Margin for this corporation currently stands at -10.82% with Operating Profit Margin at -1972.27%, Pretax Profit Margin comes in at -1754.92%, and Net Profit Margin reading is -1732.62%. To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -0.42 and Total Capital is -0.46. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.29 points at the first support level, and at 7.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.28, and for the 2nd resistance point, it is at 9.89.
Ratios To Look Out For
To put it in perspective, the Current Ratio for MoonLake Immunotherapeutics [NASDAQ:MLTX] is 16.65. Also, the Quick Ratio is 16.65, while the Cash Ratio stands at 11.21.
Transactions by insiders
Recent insider trading involved Chen Bihua, Former 10% Owner, that happened on Sep 29 ’25 when 6.49 million shares were sold. Former 10% Owner, Chen Bihua completed a deal on Sep 30 ’25 to sell 5827.0 shares. Meanwhile, Director Moukheibir Catherine sold 23500.0 shares on Jul 03 ’25.
